PREDICTORS OF MEDICATION ADHERENCE IN WOMEN WITH HIV

女性艾滋病毒感染者服药依从性的预测因素

• 批准号: 6640815
• 负责人: E S LEHMAN-TRZYNKA
• 金额: $ 1.47万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-06-01 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/6640815
• 关键词: AIDS therapy; HIV infections; antiAIDS agent; antiviral agents; behavior modification; behavior prediction; clinical research; cognition; combination chemotherapy; cues; female; functional ability; human subject; questionnaires; therapy compliance

The purpose of this study is to identify predictors of adherence to antiretroviral medications for women with HIV/AIDS. This descriptive, cross-sectional, correlation study will use Pender's Health Promotion Model (HPM) to identify predictors of adherence to combination antiretroviral medications (CAT), in a convenience sample of women with HIV/AIDS (WWHIV)living in western PA. The specific aims are to: examine the relationship between concepts identified in the HPM as cognitive-perceptual variables as predictors of adherence to CAT in WWHIV, investigate the identified cognitive-perceptual factors and investigate modification effect (cues to action) and examine the HPM as the conceptual framework. The data will be collected using Pender's Health Promotion Life-Style Profile, Morisky's Self-Report questionnaire, the Multidimensional Health Locus of Control, Laffery's Health Conception Scale, HIV Social and Emotional Aspects Questionnaire, a visual analog of perceived health status, a 3 day Recall and demographic instrument. One hundred twenty-five HIV/AIDS positive women, taking combination antiretroviral.

本研究的目的是确定感染艾滋病毒/艾滋病的女性坚持抗逆转录病毒药物治疗的预测因素。 这项描述性横断面相关性研究将使用彭德的健康促进模型 (HPM)，以生活在宾夕法尼亚州西部的艾滋病毒/艾滋病 (WWHIV) 女性患者为样本，确定坚持联合抗逆转录病毒药物 (CAT) 的预测因素。 具体目标是：检查 HPM 中确定的作为认知感知变量的概念之间的关系，作为 WWHIV 中 CAT 依从性的预测因子，调查已确定的认知感知因素并调查修改效果（行动线索），并检查 HPM 作为概念框架。 将使用 Pender 的健康促进生活方式概况、Morisky 的自我报告问卷、多维健康控制点、Laffery 的健康概念量表、HIV 社会和情感方面问卷、感知健康状况的视觉模拟、3 天回忆和人口统计工具来收集数据。 一百二十五名艾滋病毒/艾滋病阳性女性正在服用联合抗逆转录病毒药物。